DALLAS, Feb. 17, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Discovery Laboratories Inc. (Nasdaq:DSCO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/DSCO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Discovery Laboratories Inc. (DSCO) is a biotechnology company developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. Its novel technology (KL4 Surfactant Technology) produces a synthetic, peptide-containing surfactant (KL4 Surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lungs and essential for survival and normal respiratory function. In addition, its capillary aerosol generating technology (Capillary Aerosolization Technology) produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 Surfactant to the deep lung.
Message Board Search: http://www.boardcentral.com/boards/DSCO
In the report, the analyst notes:
"For the quarter ended September 30, 2009, the Company reported a net loss of $7.2 million (or $0.06 per share) on 120.0 million weighted average common shares outstanding, compared to a net loss of $10.6 million (or $0.11 per share) on 98.6 million weighted average common shares outstanding for the same period in 2008.
"DSCO announced that in response to a written guidance recently received from the U.S. Food and Drug Administration (FDA) it will now focus on a pathway that would entail solely performing additional preclinical work, instead of conducting a limited clinical trial, to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. Based on prior guidance received from the FDA, DSCO expected that a limited, pharmacodynamic-based (PD) clinical trial in preterm infants would be required to address the sole remaining Chemistry, Manufacturing & Control (CMC) issue regarding the final validation of a fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) necessary for Surfaxin approval."
To read the entire report visit: http://www.stockpreacher.com/n/DSCO
See what investors are saying about DSCO at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.